Advertisement

EMD Serono's drug candidate for treating Multiple Sclerosis has been given an extension in its FDA review period for treating relapsing MS.

The Cladribine Tablets were given priority review status by the U.S. Food and Drug Administration in July , reducing the review period from 10 months to six months. The new announcement pushes back the review deadline to February 28, 2011, from its original priority review date in November.

SOURCE

Advertisement
Advertisement